一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Investigational New Drugs >>article
Investigational New Drugs

Investigational New Drugs

IF: 3
Download PDF

Brigatinib pharmacokinetics in patients with chronic hepatic impairment.

Published:1 June 2023 DOI: 10.1007/s10637-023-01339-6 PMID: 37052729
Michael J Hanley, David Kerstein, Meera Tugnait, Narayana Narasimhan, Thomas C Marbury, Karthik Venkatakrishnan, Neeraj Gupta

Abstract

Brigatinib is an anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of ALK-positive non-small cell lung cancer. This open-label, parallel-group study investigated the effect of chronic hepatic impairment on the pharmacokinetics (PK) of brigatinib to inform dosing recommendations for these patients. Participants with hepatic impairment classified according to Child-Pugh categories of mild (A), moderate (B), or severe (C) and matched-healthy participants with normal hepatic function received a single oral dose of 90-mg brigatinib. Plasma samples were collected for the determination of brigatinib plasma protein binding and estimation of plasma PK parameters. Twenty-seven participants were enrolled (Child-Pugh A-C, n?=?6 each; matched-healthy participants, n?=?9). The mean fraction of free plasma brigatinib was comparable for the Child-Pugh A (11.1%), Child-Pugh B (10.8%), and healthy participant groups (8.5%); free brigatinib was higher in the Child-Pugh C group (23.1%). There were no clinically meaningful effects of mild or moderate hepatic impairment on unbound systemic exposures (area under the plasma concentration-time curve [AUC]) of brigatinib (geometric least-squares mean ratios [90% CI] of 89.32% [69.79%-?114.31%] and 99.55% [77.78%-127.41%], respectively). In the severe hepatic impairment group, brigatinib unbound AUC was approximately 37% higher (geometric least-squares mean ratio [90% CI] of 137.41% [107.37%-175.86%]) compared with healthy participants with normal hepatic function. Brigatinib was well tolerated in healthy participants and in participants with hepatic impairment. No dose adjustment is required for patients with mild or moderate hepatic impairment. The brigatinib dose should be reduced by approximately 40% for patients with severe hepatic impairment.

Substances (1)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Brigatinib 1197953-54-0 C29H39ClN7O2P 344 suppliers $5.00-$1504.50
南木林县| 庐江县| 莲花县| 宜宾市| 丹棱县| 丹江口市| 改则县| 星座| 天长市| 武冈市| 广水市| 增城市| 永安市| 邯郸市| 鹤山市| 竹北市| 闸北区| 花莲市| 铜鼓县| 屯门区| 蛟河市| 南靖县| 广灵县| 十堰市| 阜南县| 城市| 五台县| 新干县| 曲水县| 基隆市| 长寿区| 遂溪县| 禄劝| 兴隆县| 南康市| 岳阳市| 化德县| 海城市| 富民县| 灵武市| 班玛县|